Kristin Ann Vajda

Array ( [id] => 20692771 [patent_doc_number] => 20260124174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-05-07 [patent_title] => COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/431424 [patent_app_country] => US [patent_app_date] => 2025-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12956 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19431424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20676358 [patent_doc_number] => 20260115167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-30 [patent_title] => NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/431440 [patent_app_country] => US [patent_app_date] => 2025-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19431440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20864228 [patent_doc_number] => 12691098 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-07-28 [patent_title] => Compositions of matter and pharmaceutical compositions [patent_app_type] => utility [patent_app_number] => 19/431453 [patent_app_country] => US [patent_app_date] => 2025-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 12957 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19431453 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20881308 [patent_doc_number] => 12697327 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-08-04 [patent_title] => Pharmacological correctors of rhodopsin and uses thereof [patent_app_type] => utility [patent_app_number] => 19/370579 [patent_app_country] => US [patent_app_date] => 2025-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47626 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19370579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20498888 [patent_doc_number] => 20260028346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-01-29 [patent_title] => BTK DEGRADER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/344450 [patent_app_country] => US [patent_app_date] => 2025-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19344450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20426492 [patent_doc_number] => 20250388579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-25 [patent_title] => SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 19/309949 [patent_app_country] => US [patent_app_date] => 2025-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16631 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19309949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20150439 [patent_doc_number] => 20250250277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF [patent_app_type] => utility [patent_app_number] => 19/182366 [patent_app_country] => US [patent_app_date] => 2025-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182366 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20120397 [patent_doc_number] => 20250235428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-24 [patent_title] => NOVEL COMPOSITIONS OF MATTER AND PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 19/173537 [patent_app_country] => US [patent_app_date] => 2025-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19173537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20024849 [patent_doc_number] => 20250163071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3,-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF [patent_app_type] => utility [patent_app_number] => 19/032963 [patent_app_country] => US [patent_app_date] => 2025-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 144735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19032963 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20040846 [patent_doc_number] => 20250179068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 18/988163 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16393 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20068514 [patent_doc_number] => 20250206736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND [patent_app_type] => utility [patent_app_number] => 18/988090 [patent_app_country] => US [patent_app_date] => 2024-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18988090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20040880 [patent_doc_number] => 20250179102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-05 [patent_title] => THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 18/921239 [patent_app_country] => US [patent_app_date] => 2024-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18921239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116000 [patent_doc_number] => 12365689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof [patent_app_type] => utility [patent_app_number] => 18/913645 [patent_app_country] => US [patent_app_date] => 2024-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 49 [patent_no_of_words] => 78444 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18913645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20200340 [patent_doc_number] => 12403105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => Diagnosis and treatment of vitiligo [patent_app_type] => utility [patent_app_number] => 18/805702 [patent_app_country] => US [patent_app_date] => 2024-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 52 [patent_no_of_words] => 17063 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18805702 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769870 [patent_doc_number] => 20250051296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => MODULATORS OF MYOCYTE LIPID ACCUMULATION AND INSULIN RESISTANCE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/799659 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 396 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18799659 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19816659 [patent_doc_number] => 20250074866 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => MODIFIED AMINE LIPIDS [patent_app_type] => utility [patent_app_number] => 18/796047 [patent_app_country] => US [patent_app_date] => 2024-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56200 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18796047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20226290 [patent_doc_number] => 12414929 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Methods of treating brain disorders [patent_app_type] => utility [patent_app_number] => 18/792836 [patent_app_country] => US [patent_app_date] => 2024-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 23808 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18792836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19571823 [patent_doc_number] => 20240376115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF [patent_app_type] => utility [patent_app_number] => 18/776040 [patent_app_country] => US [patent_app_date] => 2024-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 146853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18776040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19889149 [patent_doc_number] => 20250114461 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-10 [patent_title] => CDK2 DEGRADERS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/759253 [patent_app_country] => US [patent_app_date] => 2024-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 181893 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18759253 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401292 [patent_doc_number] => 12491252 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2 [patent_app_type] => utility [patent_app_number] => 18/747376 [patent_app_country] => US [patent_app_date] => 2024-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 40 [patent_no_of_words] => 11865 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18747376 [rel_patent_id] =>[rel_patent_doc_number] =>)